Six studies [11,12,18,21,23,24] including 432 prostate cancer patients as shown in (Fig 2D) found there was a significant difference in the positive rate of CD147 expression between the two T stage groups (OR = 9.95, 95% CI 4.96–19.96, P < 0.00001) without heterogeneity (I2 = 0%, P = 0.97). Here, BSG is linked to prostate carcinoma.